We'll know more about the company's medium-term prospects by the end of the year.

The gene editing treatment targets the relatively common 1717-1G>A splicing mutation, which does not respond to many current CF therapies.

Researchers have used modified CRISPR to silence the extra chromosome 21 in Down syndrome cells, showing promising ...

Genome‑wide CRISPR screens in primary human T cells reveal human genes that promote or block HIV infection, uncovering potent ...

There are plenty of reasons, though, to be bullish on the stock, not the least of which is its improved cash position. The ...

Charles Gersbach and his colleagues are pursuing promising CRISPR technologies focused on controlling gene activity rather ...

Cancer cells excel at evading detection, but subtle chemical differences set them apart from healthy cells. Now, a team of ...

The Pairwise Fulcrum® platform includes proprietary gene editing tools, enzymes, and trait libraries that enable precise genetic changes, unlocking plants’ inherent potential and significantly ...

A growing body of research shows that cultural values strongly influence public attitudes toward CRISPR, with Japanese respondents focusing on legal frameworks and Americans on religious concerns.

Dr. Swee Lay Thein and Dr. Stuart Orkin won the $3 million Breakthrough Prize in Life Sciences for their work toward a ...

CRISPR Therapeutics AG (CRSP) closed the most recent trading day at $56.42, moving +1.58% from the previous trading session. The stock exceeded the S&P 500, which registered a gain of 1.05% for the ...

Recently, Zacks.com users have been paying close attention to CRISPR Therapeutics (CRSP). This makes it worthwhile to examine what the stock has in store.